GA-map™ Dysbiosis Test on the Luminex instrument platform.
  • 9
    May
  • Image

Luminex and GA enter into an agreement

Genetic Analysis (GA) and Luminex Corp. Inc (Luminex) has entered into an agreement whereby GA will have the right to develop, market and sell the GA-map™ Dysbiosis Test on the Luminex instrument platform.

Luminex is known for its “state of the art” technology and its instrument platforms, and have placed thousands of instruments in laboratories worldwide. We are delighted that GA will now have access to market and sell the GA-map™ Dysbiosis Test on the Luminex instruments.

In addition to market our GA-map™ Dysbiosis Test to laboratories that already have installed a Luminex instrument, GA will have the right to sell Luminex instruments to new customers. The GA-map™ Dysbiosis Test is anticipated to provide sales synergies with the Luminex products within the gastro/ intestinal area.

GA has initiated a project to document the GA-map™ test at the Luminex platform, and the plan is to complete this by the end of the year and thus start commercial sales early 2018.

 

www.luminexcorp.com

Comments are closed.